Driven to improve patients’ lives, Byondis is an independent, privately held, clinical stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) using proprietary molecular concepts, such as ByonZine®, its duocarmazine linker-drug (LD) technology and ByonShieLD®, its site-specific conjugation technology, to generate next generation antibody-drug conjugates (ADCs).
Byondis employs the latest insights in tumor biology and immunology in its search for new molecular targets and development of new mechanisms for antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs) and small molecule programs. We have a dedicated team of around 400 staff, including highly educated scientists and skilled technicians, working in our state-of-the-art R&D and manufacturing facilities at our Nijmegen campus in the Netherlands.
Transform patients' hope into reality
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. We search, research and innovate with the most talented people in our state-of-the-art research and manufacturing facilities and all share our core values: integrity, authenticity, entrepreneurship, quality and trust.
Do you have what it takes to join our team?
We are always looking for exceptional, result-oriented talents with sharp minds and entrepreneurial spirits to join us in achieving our goals. We provide an engaging, motivating, open and inspiring working environment, with room for ambition and new initiatives - leading to innovative medicines with the potential to transform patients’ lives.
Our R&D covers a wide spectrum of very diverse technologies, including complex small-molecule chemistries, medicinal chemistry, cell line development and recombinant protein production, protein purification and protein modification including conjugation, analytics, formulation and development of novel medicines. We develop new biological entities and new chemical entities and have developed a unique, proprietary linker-drug (LD) technology to generate antibody-drug conjugates (ADCs).
Byondis at a Glance
- Scientific excellence focused on a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures to create innovative precision medicines targeting relentless cancers and autoimmune diseases.
- Our oncology pipeline includes two antibody-drug conjugates (ADCs) in clinical trials. Two additional ADCs and an immuno-oncology (IO) monoclonal antibody (mAb) will enter the clinic in the coming 15 months.
- The most advanced ADC, [vic-]trastuzumab duocarmazine, is currently undergoing a pivotal Phase III clinical trial for HER2-positive locally advanced or metastatic breast cancer (TULIP®).
- Our staff of more than 400 includes highly educated scientists and skilled technicians. In-house Good Manufacturing Practice (GMP) manufacturing and conjugation facilities for both mAbs and ADCs are available, up to early commercial launch scale.